Overview
SELECT (NEJM 2023, PMID 37952131): 20% MACE reduction in non-diabetic adults with overweight/obesity + established CVD. Led to Wegovy's 2024 FDA expansion for CV risk reduction.
PubMed citations
Related clinical pages
- STEP trial results
- SELECT trial results
- FLOW trial results
- Mechanism of action
- Dosing & pharmacology
- Contraindications
- Side effects
Key facts, checked November 20, 2026
SELECT (NEJM 2023) enrolled 17,604 adults with established cardiovascular disease and overweight or obesity but no diabetes. Over a mean follow-up of 39.8 months, a major cardiovascular event occurred in 6.5% of patients on semaglutide 2.4 mg and 8.0% on placebo (hazard ratio 0.80). Adverse events led 16.6% of patients on semaglutide to stop treatment, compared with 8.2% on placebo. On this evidence the Wegovy label includes cardiovascular risk reduction. SELECT tested Wegovy, not compounded semaglutide.